Aaron Y. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron Y. Lee has a total of 730 co-authors. Here are the top co-authors by number of shared publications:
Cecilia S. Lee
John F. Hardesty M.D. Department of Ophthalmology and Visual Sciences, Washington University in St Louis School of Medicine, St. Louis MO
40 shared publications- Cecilia Sungmin Lee
John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
21 shared publications Yue Wu
Department of Ophthalmology, University of Washington, Seattle, WA, United States of America; Roger and Angie Karalis Johnson Retina Center, Seattle, WA, United States of America
20 shared publicationsMarian Blazes
Department of Ophthalmology, University of Washington, Seattle, WA, USA
15 shared publications- Adnan Tufail
NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
12 shared publications - Catherine Egan
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom
10 shared publications
Latest Publications
- Open Access
Ophthalmic AI With Just Ten Examples: Comparing Multimodal Large Language Models, Vision Foundation Models, and Vision-Language Models
Purpose: To compare multimodal large language models (MLLMs), vision foundation models (VFMs), and contrastive vision-language models (VLMs) for ophthalmic image interpretation with no labeled examples (zero-shot) or as few as 10 labeled examples per class (10-shot). Design: Retrospective benchmarking study. Subjects: 4 public datasets (UCSD, IDRiD, REFUGE, ASOCT-MSDC) and 3 private datasets (OHTS, BPEI-DLS, WashU-OCT) of anterior-and posterior-segment ophthalmic imaging. Methods: Nine AI models were evaluated across 3 architectural families: MLLMs (Qwen3.8-27B, GLM-5.3-Flash, Gemma-4-31B-it), VFMs (DINOv3, RETFound, VisionFM), and VLMs (CLIP, EyeCLIP, SigLIP2). Models were assessed on disease classification, disease risk and severity grading, anatomical assessment, and lesion localization in fundus and OCT imaging. MLLMs were also compared with a 3D VFM (OCTCube-M) for whole-volume OCT classification. MLLMs were evaluated zero-shot and 10-shot, without additional training. Vision models (VFMs and VLMs) were adapted by linear probing and fine-tuning on the same 10-shot set and on the full training dataset (FD). Main Outcome Measures: Disease classification performance (macro-averaged F1, AUROC, quadratic weighted kappa [QWK]), anatomical localization accuracy, and cross-dataset generalization. Results: For retinal OCT disease classification, 10-shot MLLMs achieved a macro-F1 of 0.94, versus 0.59 (10-shot) and 0.96 (FD) for vision models. For diabetic retinopathy and macular edema grading, 10-shot MLLMs achieved QWKs of 0.69 and 0.73, versus 0.48 and 0.57 (10-shot) and 0.72 and 0.79 (FD) for vision models. For lesion localization, 10-shot MLLMs achieved an F1 of 0.75, versus 0.70 (10-shot) and 0.86 (FD) for vision models. For vertical cup-to-disc ratio estimation (OHTS), zero-shot MLLMs achieved a mean absolute error of 0.14, versus 0.21 (10-shot) for vision models. For whole-volume OCT classification (WashU-OCT), zero-shot MLLMs achieved a macro-F1 of 0.71, versus 0.50 (10-shot) and 0.82 (FD) for vision models. Conclusions: Open-weight MLLMs given 10 labeled examples per class outperformed VFMs and VLMs trained on the same examples in most tasks and approached the performance of fully trained VFMs and VLMs in selected disease classification and grading tasks. MLLMs also demonstrated promising zero-shot performance on non-public clinical datasets without task-specific training. By reducing the need for large labeled datasets and task-specific model adaptation, MLLMs could broaden who can develop and validate ophthalmic AI.
Open AccessOphthalmic AI With Just Ten Examples: Comparing Multimodal Large Language Models, Vision Foundation Models, and Vision-Language Models
Purpose: To compare multimodal large language models (MLLMs), vision foundation models (VFMs), and contrastive vision-language models (VLMs) for ophthalmic image interpretation with no labeled examples (zero-shot) or as few as 10 labeled examples per class (10-shot). Design: Retrospective benchmarking study. Subjects: 4 public datasets (UCSD, IDRiD, REFUGE, ASOCT-MSDC) and 3 private datasets (OHTS, BPEI-DLS, WashU-OCT) of anterior-and posterior-segment ophthalmic imaging. Methods: Nine AI models were evaluated across 3 architectural families: MLLMs (Qwen3.8-27B, GLM-5.3-Flash, Gemma-4-31B-it), VFMs (DINOv3, RETFound, VisionFM), and VLMs (CLIP, EyeCLIP, SigLIP2). Models were assessed on disease classification, disease risk and severity grading, anatomical assessment, and lesion localization in fundus and OCT imaging. MLLMs were also compared with a 3D VFM (OCTCube-M) for whole-volume OCT classification. MLLMs were evaluated zero-shot and 10-shot, without additional training. Vision models (VFMs and VLMs) were adapted by linear probing and fine-tuning on the same 10-shot set and on the full training dataset (FD). Main Outcome Measures: Disease classification performance (macro-averaged F1, AUROC, quadratic weighted kappa [QWK]), anatomical localization accuracy, and cross-dataset generalization. Results: For retinal OCT disease classification, 10-shot MLLMs achieved a macro-F1 of 0.94, versus 0.59 (10-shot) and 0.96 (FD) for vision models. For diabetic retinopathy and macular edema grading, 10-shot MLLMs achieved QWKs of 0.69 and 0.73, versus 0.48 and 0.57 (10-shot) and 0.72 and 0.79 (FD) for vision models. For lesion localization, 10-shot MLLMs achieved an F1 of 0.75, versus 0.70 (10-shot) and 0.86 (FD) for vision models. For vertical cup-to-disc ratio estimation (OHTS), zero-shot MLLMs achieved a mean absolute error of 0.14, versus 0.21 (10-shot) for vision models. For whole-volume OCT classification (WashU-OCT), zero-shot MLLMs achieved a macro-F1 of 0.71, versus 0.50 (10-shot) and 0.82 (FD) for vision models. Conclusions: Open-weight MLLMs given 10 labeled examples per class outperformed VFMs and VLMs trained on the same examples in most tasks and approached the performance of fully trained VFMs and VLMs in selected disease classification and grading tasks. MLLMs also demonstrated promising zero-shot performance on non-public clinical datasets without task-specific training. By reducing the need for large labeled datasets and task-specific model adaptation, MLLMs could broaden who can develop and validate ophthalmic AI.
- Open Access
Deep Learning of Fluorescence Lifetime Imaging Ophthalmoscopy for Type 2 Diabetes Classification
Purpose: To evaluate whether fluorescence lifetime imaging ophthalmoscopy (FLIO) combined with deep learning can detect metabolic signatures for classification of type 2 diabetes mellitus (T2DM). Design: Cross-sectional analysis of participants included AI-READI dataset (version 3) with FLIO imaging and and hemoglobin A1c (HbA1c) measurement. Subjects: 1,783 participants from the AI-READI dataset (version 3) with HbA1c measurements and FLIO imaging scans (6,912 total): 671 normoglycemic, 726 prediabetic, and 386 diabetic. Methods: Mean fluorescence lifetime maps were generated using a center-of-mass approach and used as inputs to AI models. We trained convolutional neural networks (CNNs), ResNet-18, and XGBoost under three-class (normal, prediabetic, diabetic) and two binary (normal vs. impaired; normal vs. diabetic) classification schemes, using nested 5-fold cross-validation with participant-level grouping. Main Outcome Measures: Macro-averaged accuracy, F1 score, area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and positive predictive value (PPV). Results: Group-averaged lifetime maps demonstrated consistent spatial differences across glycemic groups, with progressively longer lifetimes from normal to diabetic participants. The CNN achieved the best overall performance in the 3-class classification (accuracy 0.41 ± 0.03, F1 score 0.39 ± 0.02, AUROC 0.58 ± 0.02), compared to the random classifier for 3-class classification (AUROC = 0.50; accuracy = F1 = 0.33). ResNet-18 and XGBoost showed similar performance (AUROC 0.53–0.58). Confusion matrices revealed substantial overlap between classes, with frequent misclassification toward the prediabetes group. Binary reformulation (normal vs. diabetic) improved performance substantially, with the CNN resulting in AUROC 0.63 ± 0.02 and XGBoost 0.67 ± 0.07. Conclusions: FLIO-derived lifetime maps capture metabolic signals associated with glycemic status but yield modest classification performance with current AI models. These findings highlight both the potential and the challenges of using FLIO for early metabolic screening and monitoring, informing future development of clinically applicable imaging biomarkers.
Open AccessDeep Learning of Fluorescence Lifetime Imaging Ophthalmoscopy for Type 2 Diabetes Classification
Purpose: To evaluate whether fluorescence lifetime imaging ophthalmoscopy (FLIO) combined with deep learning can detect metabolic signatures for classification of type 2 diabetes mellitus (T2DM). Design: Cross-sectional analysis of participants included AI-READI dataset (version 3) with FLIO imaging and and hemoglobin A1c (HbA1c) measurement. Subjects: 1,783 participants from the AI-READI dataset (version 3) with HbA1c measurements and FLIO imaging scans (6,912 total): 671 normoglycemic, 726 prediabetic, and 386 diabetic. Methods: Mean fluorescence lifetime maps were generated using a center-of-mass approach and used as inputs to AI models. We trained convolutional neural networks (CNNs), ResNet-18, and XGBoost under three-class (normal, prediabetic, diabetic) and two binary (normal vs. impaired; normal vs. diabetic) classification schemes, using nested 5-fold cross-validation with participant-level grouping. Main Outcome Measures: Macro-averaged accuracy, F1 score, area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and positive predictive value (PPV). Results: Group-averaged lifetime maps demonstrated consistent spatial differences across glycemic groups, with progressively longer lifetimes from normal to diabetic participants. The CNN achieved the best overall performance in the 3-class classification (accuracy 0.41 ± 0.03, F1 score 0.39 ± 0.02, AUROC 0.58 ± 0.02), compared to the random classifier for 3-class classification (AUROC = 0.50; accuracy = F1 = 0.33). ResNet-18 and XGBoost showed similar performance (AUROC 0.53–0.58). Confusion matrices revealed substantial overlap between classes, with frequent misclassification toward the prediabetes group. Binary reformulation (normal vs. diabetic) improved performance substantially, with the CNN resulting in AUROC 0.63 ± 0.02 and XGBoost 0.67 ± 0.07. Conclusions: FLIO-derived lifetime maps capture metabolic signals associated with glycemic status but yield modest classification performance with current AI models. These findings highlight both the potential and the challenges of using FLIO for early metabolic screening and monitoring, informing future development of clinically applicable imaging biomarkers.
- Open Access
Multimodal prediction of visual improvement in diabetic macular edema using real-world electronic health records and optical coherence tomography images
Multimodal learning has the potential to improve clinical prediction by integrating complementary data sources, but the incremental value of imaging beyond structured electronic health record (EHR) data remains unclear in real-world settings. We developed a multimodal survival modeling framework integrating optical coherence tomography (OCT) and EHR data to predict time to visual improvement in patients with diabetic macular edema (DME), and evaluated how different ophthalmic foundation model representations contribute to prognostic performance. In a retrospective cohort of 973 patients (1,450 eyes) receiving anti-vascular endothelial growth factor therapy, we compared multimodal models combining 22,227 EHR variables with 196,402 OCT images, with OCT embeddings derived from three ophthalmic foundation models (RETFound, EyeCLIP, and VisionFM). The EHR-only model showed minimal prognostic discrimination (C-index 0.50 [95% CI, 0.45–0.55]). Incorporating OCT improved performance, with the magnitude of improvement depending on the representation. EHR+RETFound achieved the strongest performance (C-index 0.59 [0.54–0.65]), followed by EHR+EyeCLIP (0.57 [0.52–0.62]) and EHR+VisionFM (0.56 [0.51–0.61]). Multimodal models, particularly EHR+RETFound, demonstrated improved risk stratification with clearer separation of Kaplan–Meier curves. Partial information decomposition revealed that prognostic information was dominated by modality-specific contributions, with OCT and EHR providing largely distinct signals and minimal shared information. The magnitude of OCT-specific contribution varied across foundation models and aligned with observed performance differences. These findings indicate that OCT provides complementary prognostic value beyond structured clinical data, but gains are modest and depend strongly on representation choice. Our results highlight both the promise of multimodal modeling for personalized prognosis and the need for rigorous, context-specific evaluation of foundation models in real-world clinical settings.
Open AccessMultimodal prediction of visual improvement in diabetic macular edema using real-world electronic health records and optical coherence tomography images
Multimodal learning has the potential to improve clinical prediction by integrating complementary data sources, but the incremental value of imaging beyond structured electronic health record (EHR) data remains unclear in real-world settings. We developed a multimodal survival modeling framework integrating optical coherence tomography (OCT) and EHR data to predict time to visual improvement in patients with diabetic macular edema (DME), and evaluated how different ophthalmic foundation model representations contribute to prognostic performance. In a retrospective cohort of 973 patients (1,450 eyes) receiving anti-vascular endothelial growth factor therapy, we compared multimodal models combining 22,227 EHR variables with 196,402 OCT images, with OCT embeddings derived from three ophthalmic foundation models (RETFound, EyeCLIP, and VisionFM). The EHR-only model showed minimal prognostic discrimination (C-index 0.50 [95% CI, 0.45–0.55]). Incorporating OCT improved performance, with the magnitude of improvement depending on the representation. EHR+RETFound achieved the strongest performance (C-index 0.59 [0.54–0.65]), followed by EHR+EyeCLIP (0.57 [0.52–0.62]) and EHR+VisionFM (0.56 [0.51–0.61]). Multimodal models, particularly EHR+RETFound, demonstrated improved risk stratification with clearer separation of Kaplan–Meier curves. Partial information decomposition revealed that prognostic information was dominated by modality-specific contributions, with OCT and EHR providing largely distinct signals and minimal shared information. The magnitude of OCT-specific contribution varied across foundation models and aligned with observed performance differences. These findings indicate that OCT provides complementary prognostic value beyond structured clinical data, but gains are modest and depend strongly on representation choice. Our results highlight both the promise of multimodal modeling for personalized prognosis and the need for rigorous, context-specific evaluation of foundation models in real-world clinical settings.
- 24 April 2026
- Published by Springer Nature in Nature Biomedical Engineering
A three-dimensional multi-modal foundation model for optical coherence tomography
Vision loss caused by retinal diseases remains a leading global cause of disability. Optical coherence tomography (OCT) is an imaging technique that is used for diagnosing retinal diseases. Computational models can use OCT images for various diagnostic and prognostic tasks, but most existing approaches fail to fully leverage the rich three-dimensional (3D) structure of OCT data and lack the capability to integrate other retinal imaging modalities into the analysis. Here, to address these limitations, we present OCTCube-M, a 3D OCT-based multi-modal framework designed for the integrated analysis of 3D OCT and 2D en face (EF) images. OCTCube-M exploits COEP, an effective multi-modal contrastive learning method, to integrate OCT with other retinal imaging modalities, such as fundus autofluorescence imaging and infrared retinal imaging (IR). Using the OCTCube-M framework, we developed three models: OCTCube (uni-modal), OCTCube-IR (bi-modal) and OCTCube-EF (tri-modal). OCTCube, a 3D foundation model pre-trained on 26,605 3D OCT volumes comprising 1.62 million 2D OCT slices, achieved state-of-the-art performance in predicting 8 retinal diseases while demonstrating robust generalizability across cohorts, devices and modalities. OCTCube-IR extends OCTCube by incorporating 26,685 pairs of OCT and IR images, enabling accurate cross-modality retrieval and joint analysis of these two modalities. OCTCube-EF, trained on over 4 million 2D OCT slices and 400 thousand EF retinal images, excels in predicting the growth rate of geographic atrophy across datasets collected from 6 multi-centre clinical trials across 23 countries. Collectively, OCTCube-M is a 3D multi-modal foundation model framework for integrating OCT and other retinal imaging modalities. It demonstrated substantial advancements in cross-site, cross-device, cross-modality and systemic disease prediction, while offering substantial utility in geographic atrophy clinical trials.
- 24 April 2026
- Published by Springer Nature in Nature Biomedical Engineering
A three-dimensional multi-modal foundation model for optical coherence tomography
Vision loss caused by retinal diseases remains a leading global cause of disability. Optical coherence tomography (OCT) is an imaging technique that is used for diagnosing retinal diseases. Computational models can use OCT images for various diagnostic and prognostic tasks, but most existing approaches fail to fully leverage the rich three-dimensional (3D) structure of OCT data and lack the capability to integrate other retinal imaging modalities into the analysis. Here, to address these limitations, we present OCTCube-M, a 3D OCT-based multi-modal framework designed for the integrated analysis of 3D OCT and 2D en face (EF) images. OCTCube-M exploits COEP, an effective multi-modal contrastive learning method, to integrate OCT with other retinal imaging modalities, such as fundus autofluorescence imaging and infrared retinal imaging (IR). Using the OCTCube-M framework, we developed three models: OCTCube (uni-modal), OCTCube-IR (bi-modal) and OCTCube-EF (tri-modal). OCTCube, a 3D foundation model pre-trained on 26,605 3D OCT volumes comprising 1.62 million 2D OCT slices, achieved state-of-the-art performance in predicting 8 retinal diseases while demonstrating robust generalizability across cohorts, devices and modalities. OCTCube-IR extends OCTCube by incorporating 26,685 pairs of OCT and IR images, enabling accurate cross-modality retrieval and joint analysis of these two modalities. OCTCube-EF, trained on over 4 million 2D OCT slices and 400 thousand EF retinal images, excels in predicting the growth rate of geographic atrophy across datasets collected from 6 multi-centre clinical trials across 23 countries. Collectively, OCTCube-M is a 3D multi-modal foundation model framework for integrating OCT and other retinal imaging modalities. It demonstrated substantial advancements in cross-site, cross-device, cross-modality and systemic disease prediction, while offering substantial utility in geographic atrophy clinical trials.
- Open Access
- 17 April 2026
- Published by Elsevier in Ophthalmology
- Vol. 133  (7) , 865-873
Reference Standard for Validation of Age-Related Macular Degeneration Screening Algorithms
- 17 April 2026
- Published by Elsevier in Ophthalmology
- Vol. 133  (7) , 865-873
Open AccessReference Standard for Validation of Age-Related Macular Degeneration Screening Algorithms
- Open Access
A Manual of Procedures for the Generation of the AI-Ready and Exploratory Atlas for Diabetes Insights (AI-READI) Database
The ability to understand and affect the course of complex, multi-system diseases like diabetes has been limited by a lack of well-designed, high-quality and large multimodal datasets. The NIH Bridge2AI AI-READI project ( aireadi.org ) aims to address this shortfall by generating an AI-ready dataset to support AI discoveries in type 2 diabetes mellitus (T2DM). This manual of procedures provides a detailed description of the AI-READI protocol.
Open AccessA Manual of Procedures for the Generation of the AI-Ready and Exploratory Atlas for Diabetes Insights (AI-READI) Database
The ability to understand and affect the course of complex, multi-system diseases like diabetes has been limited by a lack of well-designed, high-quality and large multimodal datasets. The NIH Bridge2AI AI-READI project ( aireadi.org ) aims to address this shortfall by generating an AI-ready dataset to support AI discoveries in type 2 diabetes mellitus (T2DM). This manual of procedures provides a detailed description of the AI-READI protocol.
- Open Access
An LLM-assisted framework for accelerated and verifiable clinical hypothesis testing from electronic health records
Acquiring insights from electronic health records (EHRs) is slowed by manual analytical workflows that limit scalability and reproducibility. We present LATCH (LLM-Assisted Testing of Clinical Hypotheses), an agentic framework that converts natural language clinical hypotheses into fully auditable analyses on structured EHR data. LATCH integrates LLM-assisted semantic layers with deterministic execution pipelines to automate cohort construction, statistical analysis, and result reporting, while isolating patient-level data from LLM-involved steps. Using diabetes as a model disease, LATCH reproduced findings from 20 published studies within 3-15 minutes per study. Beyond replication, LATCH enabled study extensions and new insight generation through simple natural language hypothesis modifications. We demonstrated LATCH across 102 hypothesis tests spanning reproduction, extension, and insight generation. We systematically stress-tested LATCH to characterize its limitations and operational boundaries. LATCH provides a scalable framework for reproducible real-world evidence generation, reducing analytical bottlenecks and improving reliability of AI-assisted biomedical discovery while preserving human oversight.
Open AccessAn LLM-assisted framework for accelerated and verifiable clinical hypothesis testing from electronic health records
Acquiring insights from electronic health records (EHRs) is slowed by manual analytical workflows that limit scalability and reproducibility. We present LATCH (LLM-Assisted Testing of Clinical Hypotheses), an agentic framework that converts natural language clinical hypotheses into fully auditable analyses on structured EHR data. LATCH integrates LLM-assisted semantic layers with deterministic execution pipelines to automate cohort construction, statistical analysis, and result reporting, while isolating patient-level data from LLM-involved steps. Using diabetes as a model disease, LATCH reproduced findings from 20 published studies within 3-15 minutes per study. Beyond replication, LATCH enabled study extensions and new insight generation through simple natural language hypothesis modifications. We demonstrated LATCH across 102 hypothesis tests spanning reproduction, extension, and insight generation. We systematically stress-tested LATCH to characterize its limitations and operational boundaries. LATCH provides a scalable framework for reproducible real-world evidence generation, reducing analytical bottlenecks and improving reliability of AI-assisted biomedical discovery while preserving human oversight.
- Top Cited Papers
- 21 January 2026
- Published by Elsevier in Ophthalmology
- Vol. 133  (6) , 733-741
A Framework for Healthcare from the Eye
- 21 January 2026
- Published by Elsevier in Ophthalmology
- Vol. 133  (6) , 733-741
Top Cited PapersA Framework for Healthcare from the Eye
- 14 January 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20  (3) , 609-619
Research Code Sharing in Support of Gold Standard Science
Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.
- 14 January 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20  (3) , 609-619
Research Code Sharing in Support of Gold Standard Science
Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.
- 4 December 2025
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 110, 101419
Beyond convolutions and supervised learning with transformers and representation learning for retinal image analysis
- 4 December 2025
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 110, 101419
Beyond convolutions and supervised learning with transformers and representation learning for retinal image analysis